Evolution of Antarctic Candida lipase B and its catalytic synthesis of (S)-1,4-benzodioxane

By modifying the mutants D223N/A225K and E188D/I189M of Candida antarcticis lipase B, the problem of insufficient enantioselectivity in the enzymatic catalytic kinetic resolution of 1,4-benzodioxane compounds was solved, achieving efficient enantioselective resolution and meeting the needs of drug synthesis.

CN117004679BActive Publication Date: 2026-11-17SHANGHAI JIAOTONG UNIV
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202210469532.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-04-28
Publication Date
2026-11-17
Estimated Expiration
2042-04-28

AI Technical Summary

Technical Problem

Existing enantioselectivity for the enzymatic catalytic kinetic resolution of 1,4-benzodioxane compounds is limited, making it difficult to meet the high-efficiency manufacturing requirements of drug synthesis.

Method used

By performing directed evolutionary modification of Candida antarcticis lipase B, mutants such as D223N/A225K and E188D/I189M were developed. The enzymatic kinetics of catalytic resolution of (R,S)-1,4-benzodioxane-2-carboxylate were optimized, improving enantiomeric selectivity.

Benefits of technology

Efficient resolution of (R,S)-1,4-benzodioxane-2-carboxylic acid methyl ester was achieved. The mutant showed significantly improved selectivity for (S)- or (R)-1,4-benzodioxane-2-carboxylic acid, achieving a high ees value, which meets the requirements of drug synthesis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

This invention provides *Candida antarcticus* lipase B and its mutants, as well as their preparation methods and applications. Specifically, this invention relates to the in vitro directed evolution of *Candida antarcticus* lipase B and its application in the catalytic kinetic resolution of (R,S)-1,4-benzodioxane-2-carboxylate for the synthesis of chiral drug intermediates, and the optimization of its conditions. This invention also provides a method for the in vitro kinetic resolution reaction. The enzyme and mutants of this invention can be used for the in vitro enzymatic synthesis of (R)- or (S)-1,4-benzodioxane molecules.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the fields of molecular biology and biocatalysis, specifically relating to the application of *Candida antarcticus* lipase B in catalyzing the kinetic resolution of methyl (R,S)-1,4-benzodioxane-2-carboxylate. This invention provides *Candida antarcticus* lipase B and its mutants, and its catalytic activity in resolving methyl (R,S)-1,4-benzodioxane-2-carboxylate. Background Technology

[0002] 1,4-Benzodioxane is a widely used multifunctional structural module in medicinal chemistry for the synthesis of various bioactive compounds. 1,4-Benzodioxane derivatives possess bioactivities such as prostaglandin I2 inducer, neurotrophic agent, anti-angiogenic agent, and antioxidant agent, and can be used as antitumor drugs and antibacterial agents. Studies have found that its S and R configurations have different functions; for example, (S)-configuration 1,4-Benzodioxane derivatives such as Proroxan and Doxazosin have stronger antihypertensive functions, while the (R)-configuration MCK-242 is an important component of antidepressants. Therefore, the preparation of 1,4-Benzodioxanes with specific chiral configurations is of great significance to the pharmaceutical industry.

[0003] Currently, 1,4-benzodioxane compounds are mainly obtained through chemical methods, including asymmetric synthesis, crystallization, racemic resolution, chiral cell analysis, and chiral HPLC, to obtain chiral molecules with specific configurations. However, these processes suffer from drawbacks such as low enantioselectivity, numerous toxic byproducts, complex subsequent purification steps, and high costs. Therefore, establishing green and efficient enzymatic synthesis methods has attracted widespread attention from researchers. Rouf et al. used Arthrobacter-derived lipases to catalyze the kinetic resolution of (R,S)-1,4-benzodioxane-2-carboxylate, synthesizing the (S)-enantiomer containing the 1,4-benzodioxane skeleton, achieving a conversion rate of 42% and an ee of 73%. s Value; Kalkote et al. used an Alcaligenes-derived lipase to hydrolyze the doxazosin mesylate intermediate (R,S)-methyl-1,4-benzodioxin-2-carboxylate to obtain the (S)-type acid, achieving an ee of 89%. s The values ​​were obtained, but no conversion rates were recorded. However, the enantioselectivity of enzymatic catalytic kinetic resolution reported in the current literature remains limited and cannot meet the requirements for efficient drug manufacturing. Therefore, further molecular modification of candidate enzymes is urgently needed to achieve the precise synthesis of optically pure 1,4-benzodioxane compounds with specific configurations.

[0004] Candida antarctica lipase B (CalB) is a microbial lipase with high catalytic activity, and its successful application in the kinetic resolution of chiral drugs has been reported. Sikora et al. used wild-type CalB to catalyze the kinetic resolution of the β-receptor blocker (R,S)-propranolol, obtaining (S)-propranolol acetate. The product's ee... s The enantioselectivity reached 90.1%; however, for the synthesis of other drugs, molecular modification is still necessary due to the low stereoselectivity of the substrate binding pocket. For example, Liu et al. constructed the CalB mutant EF5 through semi-rational design, which improved the selectivity for (R)-type 3-substituted glutaric acid monoesters. Further, using molecular docking and other methods, they determined that mutations in two key residues, D223 and A281, on the active pocket and substrate channel could reduce conformational kinetic parameters, resulting in the mutant D223V / A281S with higher R enantioselectivity (>99.00%). Marton et al. found that mutants I189A, L278V, and A282L altered the width and shape of the hydrophobic channel leading to the active site, leading to changes in enantioselectivity. Furthermore, Shen et al. constructed the CalB mutant I189K, achieving 583.8 g L... -1 d -1 The yield of moxifloxacin chiral intermediates was measured. Wu et al. predicted the correlation between the E188 site and enantioselectivity, and Katarzyna et al. found that E188 is important for enzyme-substrate binding. Wu et al. also found that the CalB mutant A225M has higher selectivity (>90%) for (S)-type 1,4-benzodioxane. In addition, Magnusson et al., through rational design, found that residue mutations near the catalytic active site (catalytic triplet S105-D187-H224) have a major impact on substrate stereoselectivity.

[0005] Currently, there is still room for improvement in the enantioselectivity of enzymatic catalytic kinetic resolution reported in the literature. Therefore, it is urgent to further modify enzyme molecules to achieve higher enantioselectivity. Summary of the Invention

[0006] The purpose of this invention is to provide a method for preparing Candida antarctica lipase B and its mutants, as well as a method and optimized conditions for the kinetic resolution of (R,S)-1,4-benzodioxane-2-carboxylate ester.

[0007] In a first aspect of the present invention, an enzymatic catalytic kinetic resolution method is provided, comprising the steps of:

[0008] (a) In the presence of Candida antarcticis lipase B or its mutant, the substrate (R,S)-1,4-benzodioxane-2-carboxylate was subjected to an enzymatic kinetic resolution reaction to form a reaction mixture containing the trans product (S)-1,4-benzodioxane-2-carboxylic acid.

[0009]

[0010] In the reaction mixture, the ratio of the amount of (S)-1,4-benzodioxane-2-carboxylic acid (compound of formula (S)-2) A1 to the amount of (R)-1,4-benzodioxane-2-carboxylic acid A2 is A1 / A2 ≥ 2:1.

[0011] In another preferred embodiment, the mutant has a mutation at a site selected from the group consisting of: position 223, position 225, or a combination thereof, wherein the site is based on the wild-type Candida antarcticis lipase B sequence shown in SEQ ID No:1.

[0012] In another preferred embodiment, the mutant has a mutation at position 223 selected from the group consisting of: D223N, D223G, D223S, D223R, and D223T.

[0013] In another preferred embodiment, the mutant has a 225-position mutation selected from the group consisting of: A225K, A225R, A225W, and A225Y.

[0014] In another preferred embodiment, the mutant has mutations selected from the group consisting of: D223N / A225K, D223G / A225W, D223S / A225W, D223G / A225Y, D223N / A225Y, D223S / A225R, D223S / A225Y, D223G / A225K, D223R / A225R, D223R / A225W, and D223T / A225Y.

[0015] In another preferred embodiment, the mutant has the following mutation: D223N / A225K, wherein the site is based on the wild-type Candida antarcticis lipase B sequence shown in SEQ ID No:1.

[0016] In another preferred embodiment, the amino acid sequence of the mutant (the mutant Candida antarcticis lipase B of D223N / A225K) is shown in SEQ ID No:2.

[0017] In another preferred embodiment, the mutant has the following mutation: E188Q / I189T, wherein the site is based on the wild-type Candida antarctic lipase B sequence shown in SEQ ID No:1.

[0018] In another preferred embodiment, the amino acid sequence of the mutant (the mutant Candida antarcticis lipase B of E188Q / I189T) is shown in SEQ ID No:3.

[0019] In another preferred embodiment, the mutant has the above-mentioned mutations at positions 223 and / or 225, and further has the E188Q / I189T mutation.

[0020] In another preferred embodiment, the mutant has D223N / A225K and E188Q / I189T mutations, wherein the sites are based on the wild-type Candida antarcticis lipase B sequence shown in SEQ ID No:1.

[0021] In another preferred embodiment, the mutant exhibits superior selectivity for the resolution of (S)-1,4-benzodioxane-2-carboxylic acid compared to wild-type Candida antarctic lipase B.

[0022] In another preferred embodiment, the ratio (Y1 / Y0) of the resolution selectivity Y1 of the mutant for (S)-1,4-benzodioxane-2-carboxylic acid to the resolution selectivity Y0 of wild-type Candida antarctica lipase B for (S)-1,4-benzodioxane-2-carboxylic acid is ≥1.2, preferably ≥1.5, more preferably ≥2.0 (e.g., 1.2-5, preferably 1.5-3.0, more preferably 2.0-2.5).

[0023] In another preferred embodiment, the mutant retains the wild-type Candida antarctic lipase B's resolving selectivity for (S)-1,4-benzodioxane-2-carboxylic acid.

[0024] In another preferred embodiment, step (a) is carried out in a liquid-phase reaction system.

[0025] In another preferred embodiment, the solvent of the liquid-phase reaction system is selected from the group consisting of DMSO, n-butanol, isopropanol, ethyl acetate, chloroform, etc.

[0026] In another preferred embodiment, in step (a), the reaction temperature is 30-45°C, more preferably 33-42°C, and even more preferably 35-39°C.

[0027] In another preferred embodiment, in step (a), the reaction time is 40-60 min.

[0028] In another preferred embodiment, the method further includes the step of:

[0029] (b) The trans product (S)-1,4-benzodioxane-2-carboxylic acid was isolated from the reaction mixture.

[0030] In a second aspect of the present invention, an enzymatic catalytic kinetic resolution method is provided, comprising the steps of:

[0031] (a) In the presence of a selective reverse mutant of Candida antarcticis lipase B, the substrate (R,S)-1,4-benzodioxane-2-carboxylic acid methyl ester underwent an enzymatic kinetic resolution reaction to form a reaction mixture containing the trans product (R)-1,4-benzodioxane-2-carboxylic acid.

[0032]

[0033] In the reaction mixture, the ratio of the amount of (R)-1,4-benzodioxane-2-carboxylic acid A2 to the amount of (S)-1,4-benzodioxane-2-carboxylic acid A1 is A2 / A1 ≥ 1:1.

[0034] In another preferred embodiment, the selective inversion mutant has mutations selected from the group consisting of: E188D / I189M, E188N / I189Y, E188D / I189Y, and E188D / I189F, wherein the site is based on the wild-type Candida antarcticis lipase B sequence shown in SEQ ID No:1.

[0035] In another preferred embodiment, step (a) is carried out in a liquid-phase reaction system.

[0036] In another preferred embodiment, the solvent of the liquid-phase reaction system is selected from the group consisting of DMSO, n-butanol, isopropanol, ethyl acetate, chloroform, etc.

[0037] In another preferred embodiment, in step (a), the reaction temperature is 30-45°C, more preferably 33-42°C, and even more preferably 35-39°C.

[0038] In another preferred embodiment, in step (a), the reaction time is 40-60 min.

[0039] In another preferred embodiment, the method further includes the step of:

[0040] (b) The trans product (S)-1,4-benzodioxane-2-carboxylic acid was isolated from the reaction mixture.

[0041] In a third aspect of the invention, an isolated or purified Candida antarcticis lipase B (CalB) mutant is provided, said mutant being selected from the group consisting of:

[0042] (i) An Antarctic Candida lipase B mutant with D223N / A225K;

[0043] (ii) Antarctic Candida lipase B mutant with E188Q / I189T;

[0044] The amino acid number is based on the amino acid sequence of wild-type Candida antarcticis lipase B (CalB) shown in SEQ ID No:1;

[0045] In another preferred embodiment, the amino acid sequence of the mutant Candida antarcticis lipase B mutant with D223N / A225K is shown in SEQ ID No:2;

[0046] In another preferred embodiment, the amino acid sequence of the mutant Candida antarcticis lipase B mutant with E188Q / I189T is shown in SEQ ID No:3.

[0047] In a fourth aspect of the invention, an isolated or purified Candida antarcticis lipase B (CalB) mutant is provided, said mutant being a Candida antarcticis lipase B mutant having mutations selected from the following group:

[0048] E188D / I189M, E188N / I189Y, E188D / I189Y or E188D / I189F;

[0049] The amino acid number is based on the amino acid sequence of wild-type Candida antarcticis lipase B shown in SEQ ID No:1.

[0050] In another preferred embodiment, the fourth aspect mutant is based on a reversed hydrolysis preference, unlike wild-type CalB, that is, preferential hydrolysis of R-configuration substrates.

[0051] In a fifth aspect of the invention, an isolated polynucleotide is provided, said polynucleotide encoding the Candida antarcticis lipase B (CalB) mutant described in the third or fourth aspect of the invention.

[0052] In another preferred embodiment, the sequence of the polynucleotide encoding mutant Candida antarctic lipase B is substantially the same as that of SEQ ID NO:4, except that the codons encoding mutant amino acids at specific sites are different (for example, for the D223N / A225K mutant Candida antarctic lipase B, the codon corresponding to amino acid 223 is the codon encoding amino acid N, and the codon corresponding to amino acid 225 is the codon encoding amino acid K).

[0053] In a sixth aspect of the invention, a carrier is provided, said carrier containing the polynucleotide described in the fifth aspect of the invention.

[0054] In a seventh aspect of the invention, a genetically engineered host cell is provided, said host cell containing the vector described in the sixth aspect of the invention, or having the polynucleotides described in the fifth aspect of the invention integrated into its genome.

[0055] In an eighth aspect of the invention, the use of the Candida antarcticis lipase B (CalB) mutant described in the third or fourth aspect of the invention is provided, which is used for catalytic kinetic resolution reactions or for the preparation of catalysts for catalytic kinetic resolution reactions.

[0056] In another preferred embodiment, the substrate for the kinetic resolution reaction includes methyl (R,S)-1,4-benzodioxane-2-carboxylate.

[0057] In another preferred embodiment, the Candida antarcticis lipase B (CalB) mutant is used to preferentially degrade (R)-1,4-benzodioxane-2-carboxylate more than wild-type CalB.

[0058] In another preferred embodiment, the selective reversal of the Candida antarcticis lipase B (CalB) mutant is used for preferential degradation of (S)-1,4-benzodioxane-2-carboxylate.

[0059] In a ninth aspect of the invention, a reaction system for carrying out a kinetic resolution reaction is provided, the reaction system comprising:

[0060] (Z1) an enzyme selected from the group consisting of: Candida antarcticis lipase B or a mutant thereof; and

[0061] (Z2)(R,S)-1,4-benzodioxane-2-carboxylic acid methyl ester substrate.

[0062] In another preferred embodiment, the mutant is the Candida antarcticis lipase B (CalB) mutant described in the third or fourth aspect of the present invention.

[0063] In another preferred embodiment, the reaction system further includes:

[0064] (Z3) solvent;

[0065] (Z4) Phosphate buffer mixture.

[0066] In another preferred embodiment, the solvent is selected from organic solvents from the group consisting of DMSO, n-butanol, isopropanol, ethyl acetate, chloroform, or combinations thereof.

[0067] In another preferred embodiment, the solvent is a two-phase solvent system.

[0068] It should be understood that, within the scope of this invention, the above-described technical features of this invention and the technical features specifically described below (such as in the embodiments) can be combined with each other to form new or preferred technical solutions. Due to space limitations, they will not be described in detail here. Attached Figure Description

[0069] Figure 1 The image shows the SDS-PAGE electrophoresis results of purified Candida antarcticis lipase B.

[0070] Figure 2 The conversion of (R,S)-1,4-benzodioxane-2-carboxylic acid to (S)-1,4-benzodioxane-2-carboxylic acid catalyzed by *Candida antarcticus* lipase B and its mutant is shown in relation to ee. s value.

[0071] Figure 3 This study demonstrates the ee catalytic kinetics of the resolution of methyl (R,S)-1,4-benzodioxane-2-carboxylate to (R)-1,4-benzodioxane-2-carboxylic acid by *Candida antarcticus* lipase B and its configuration-reversal-preferred mutant. s value.

[0072] Figure 4 The effect of temperature on the catalytic kinetics of the resolution of wild-type and mutant Candida antarcticis lipase B was shown.

[0073] Figure 5 The effect of cosolvent type on the catalytic kinetics of the resolution of wild-type and mutant Candida antarcticis lipase B was shown.

[0074] Figure 6 The effect of co-solvent percentage on the catalytic kinetics of Candida antarctica lipase B wild-type and mutant D223N / A225K resolution was shown.

[0075] Figure 7 The time course of the kinetic resolution of (R,S)-1,4-benzodioxane-2-carboxylate catalyzed by wild-type and mutant Candida antarctica lipase B is shown. Detailed Implementation

[0076] Through extensive and in-depth research and screening, the inventors have unexpectedly developed, for the first time, a method for selectively resolving (R,S)-1,4-benzodioxane-2-carboxylate via enzymatic kinetics. Specifically, the inventors discovered that *Candida antarcticus* lipase B and its mutants exhibit resolution selectivity for (R,S)-1,4-benzodioxane-2-carboxylate. The inventors also performed directed evolutionary modification of *Candida antarcticus* lipase B, obtaining mutant proteins with improved enantiomeric selectivity (such as selective ee). s The mutant D223N / A225K showed a significantly increased value. Furthermore, the inventors unexpectedly obtained a mutant E188D / I189M of *Candida antarcticus* lipase B with reversed substrate selectivity for (R,S)-1,4-benzodioxane-2-carboxylic acid methyl ester. The *Candida antarcticus* lipase B and its mutants of this invention can be used for the in vitro enzymatic selective synthesis of p-S- or R-form 1,4-benzodioxane-2-carboxylic acid. This invention was completed based on these findings.

[0077] definition

[0078] As used herein, the terms “Candida antarcticis lipase B mutant,” “Candida antarcticis lipase B mutant protein,” and “mutant Candida antarcticis lipase B” are used interchangeably to refer to a mutant protein that has one or more amino acid substitutions, deletions, or insertions compared to the amino acid sequence of wild-type Candida antarcticis lipase B.

[0079] As used in this article, "ee value" is an abbreviation for enantiomeric excess, which refers to the enantiomeric excess rate and is defined as the percentage of the total amount of one isomer a that is more than another isomer b in an enantiomeric mixture.

[0080] As used in this article, "ee" s "Value" refers to the substrate excess rate, defined as the percentage of the total amount of R-isomers that are more abundant than S-isomers in a substrate enantiomer mixture.

[0081]

[0082] A S and A R These represent the amounts of unhydrolyzed R-configured and S-configured substrates in the substrate after the reaction, respectively. Taking (R,S)-1,4-benzodioxane-2-carboxylate as an example, the R-configured substrate refers to (R)-1,4-benzodioxane-2-carboxylate, while the S-configured substrate refers to (S)-1,4-benzodioxane-2-carboxylate.

[0083] Protein of the present invention

[0084] As used herein, the term "invention protein" refers to Candida antarcticis lipase B or a mutant thereof.

[0085] In this invention, a particularly preferred class of proteins is

[0086] (i) An Antarctic Candida lipase B mutant with D223N / A225K;

[0087] (ii) Antarctic Candida lipase B mutant with E188Q / I189T.

[0088] As used herein, "isolated polypeptide" means that the polypeptide is substantially free of other naturally occurring or associated proteins, lipids, carbohydrates, or other substances. Those skilled in the art can purify the polypeptide using standard protein purification techniques. A substantially pure polypeptide will produce a single master band on a non-reducing polyacrylamide gel. The purity of the polypeptide can also be further analyzed using its amino acid sequence.

[0089] The active polypeptides of the present invention can be recombinant polypeptides, natural polypeptides, or synthetic polypeptides. The polypeptides of the present invention can be naturally purified products, chemically synthesized products, or produced from a prokaryotic or eukaryotic host (e.g., bacteria, yeast, plants) using recombinant technology. Depending on the host used in the recombinant production protocol, the polypeptides of the present invention can be dehydrated or non-dehydrated. The polypeptides of the present invention may or may not include an initial methionine residue.

[0090] The present invention also includes fragments, derivatives, and analogs of the said polypeptide. As used herein, the terms “fragment,” “derivative,” and “analyte” refer to a polypeptide that substantially retains the same biological function or activity as the said polypeptide.

[0091] The polypeptide fragments, derivatives, or analogs of the present invention may be (i) polypeptides in which one or more conserved or non-conserved amino acid residues (preferably conserved amino acid residues) are substituted, and such substituted amino acid residues may or may not be encoded by the genetic code; or (ii) polypeptides having substituent groups in one or more amino acid residues; or (iii) polypeptides formed by fusing a mature polypeptide with another compound (e.g., a compound that extends the half-life of the polypeptide, such as polyethylene glycol); or (iv) polypeptides formed by fusing an additional amino acid sequence to the polypeptide sequence (e.g., a leader sequence or secretion sequence or a sequence used to purify the polypeptide or a proteogen sequence, or a fusion protein formed with an antigen IgG fragment). Based on the teachings herein, these fragments, derivatives, and analogs are within the scope well known to those skilled in the art.

[0092] The preferred sequence of the polypeptide is the polypeptide shown in SEQ ID NO:2 or 3. This term also includes variants and derived polypeptides having the same function as the polypeptide shown, and of the sequence SEQ ID NO:2 or 3. These variants include (but are not limited to): deletions, insertions, and / or substitutions of one or more amino acids (typically 1-50, preferably 1-30, more preferably 1-20, most preferably 1-10); and the addition of one or more amino acids (typically up to 20, preferably up to 10, more preferably up to 5) at the C-terminus and / or N-terminus.

[0093] For example, in the art, substitution with amino acids of similar or identical properties typically does not alter the function of a protein. Similarly, adding one or more amino acids to the C-terminus and / or N-terminus typically does not change the function of a protein. This term also includes the active fragment and active derivatives of the *Candida antarcticis* lipase B (CalB) of this invention. The invention also provides analogs of the said polypeptide.

[0094] These polypeptides include natural or induced genetic variants. Induced variants can be obtained by various techniques, such as random mutagenesis through radiation or exposure to a mutagen, or by site-directed mutagenesis or other known molecular biology techniques. Analogs also include those having residues different from naturally occurring L-amino acids (such as D-amino acids), and those having non-naturally occurring or synthetic amino acids (such as β, γ-amino acids). It should be understood that the polypeptides of the present invention are not limited to the representative polypeptides exemplified above.

[0095] Modifications (typically without altering the primary structure) include: chemically derived forms of peptides, either in vivo or in vitro, such as acetylation or carboxylation. Modifications also include sequences containing phosphorylated amino acid residues (such as phosphotyrosine, phosphotyserine, phosphotythreonine). They also include peptides modified to improve their resistance to proteolysis or optimize their solubility.

[0096] The amino or carboxyl terminus of the protein of this invention may also contain one or more polypeptide fragments as protein tags. Any suitable tag can be used in this invention. For example, the tags may be FLAG, HA, HA1, c-Myc, Poly–His, Poly-Arg, Strep-TagII, AU1, EE, T7, 4A6, ε, B, gE, and Ty1. These tags can be used for protein purification.

[0097] To enable the translated protein to be expressed secretively (e.g., secreted extracellularly), a signal peptide sequence, such as the pelB signal peptide, can be added to the amino terminus of the *Candida antarcticis* lipase B (CalB). The signal peptide can be cleaved during the secretion of the polypeptide from the cell.

[0098] The polynucleotides of this invention can be in DNA or RNA form. DNA form includes cDNA, genomic DNA, or artificially synthesized DNA. DNA can be single-stranded or double-stranded. DNA can be a coding strand or a non-coding strand.

[0099] Taking the mutant CalB encoding D223N / A225K as an example, the coding region sequence encoding the mature polypeptide can be the same as the coding region sequence shown in SEQ ID NO:2 or a degenerate variant. As used herein, "degenerate variant" refers to a nucleic acid sequence that encodes the protein having SEQ ID NO:2 but differs from the coding region sequence shown in SEQ ID NO:4.

[0100] The polynucleotide encoding the mature polypeptide of SEQ ID NO:1 includes: a coding sequence that encodes only the mature polypeptide; a coding sequence of the mature polypeptide and various additional coding sequences; a coding sequence of the mature polypeptide (and optional additional coding sequences) and a non-coding sequence.

[0101] The term "polynucleotide encoding a polypeptide" can refer to a polynucleotide that includes the polypeptide, or it can also include additional coding and / or non-coding sequences.

[0102] This invention also relates to variants of the aforementioned polynucleotides that encode polypeptides or fragments, analogs, and derivatives of polypeptides having the same amino acid sequence as those of this invention. These polynucleotide variants can be naturally occurring isoforms or non-naturally occurring variants. These nucleotide variants include substitution variants, deletion variants, and insertion variants. As is known in the art, an allelic variant is a substitution of a polynucleotide, which may be a substitution, deletion, or insertion of one or more nucleotides, but does not substantially alter the function of the polypeptide it encodes.

[0103] The present invention also relates to polynucleotides that hybridize with the above-described sequences and have at least 50%, preferably at least 70%, and more preferably at least 80% identity between the two sequences. The present invention particularly relates to polynucleotides that hybridize with the polynucleotides described herein under stringent conditions (or strict conditions). In the present invention, “stringent conditions” means: (1) hybridization and elution at lower ionic strength and higher temperatures, such as 0.2×SSC, 0.1% SDS, 60°C; or (2) hybridization with a denaturing agent, such as 50% (v / v) formamide, 0.1% fetal bovine serum / 0.1% Ficoll, 42°C, etc.; or (3) hybridization only occurs when the identity between the two sequences is at least 90%, more preferably at least 95%. Furthermore, the polypeptide encoded by the hybridizable polynucleotide has the same biological function and activity as the mature polypeptide shown in SEQ ID NO:1.

[0104] This invention also relates to nucleic acid fragments that hybridize with the sequences described above. As used herein, a “nucleic acid fragment” is at least 15 nucleotides long, preferably at least 30 nucleotides, more preferably at least 50 nucleotides, and most preferably at least 100 nucleotides or more. The nucleic acid fragment can be used in nucleic acid amplification techniques (such as PCR) to identify and / or isolate polynucleotides encoding Candida antarctica lipase B (CalB) protein.

[0105] The polypeptides and polynucleotides in this invention are preferably provided in isolated form, and more preferably purified to homogenization. The full-length nucleotide sequence or fragments of the *Candida antarcticis* lipase B (CalB) of this invention can generally be obtained by PCR amplification, recombinant methods, or artificial synthesis. For PCR amplification, primers can be designed based on the relevant nucleotide sequences disclosed in this invention, especially the open reading frame sequences, and the relevant sequences can be amplified using commercially available cDNA libraries or cDNA libraries prepared according to conventional methods known to those skilled in the art as templates. When the sequence is long, it is often necessary to perform two or more PCR amplifications, and then splice the fragments amplified from each amplification in the correct order.

[0106] Once the relevant sequence is obtained, it can be obtained in large quantities using recombination methods. This typically involves cloning it into a vector, transforming it into cells, and then isolating the relevant sequence from the proliferated host cells using conventional methods.

[0107] In addition, sequences can be synthesized artificially, especially when the fragment length is short. Typically, long sequences can be obtained by first synthesizing multiple small fragments and then joining them.

[0108] Currently, the DNA sequence encoding the protein of the present invention (or a fragment thereof, or a derivative thereof) can be obtained entirely through chemical synthesis. This DNA sequence can then be introduced into various existing DNA molecules (or vectors, etc.) and cells known in the art. Furthermore, mutations can be introduced into the protein sequence of the present invention through chemical synthesis. The method of amplifying DNA / RNA using PCR technology is preferred for obtaining the gene of the present invention. Especially when it is difficult to obtain full-length cDNA from a library, the RACE method (RACE-cDNA end amplification method) is preferred. Primers used for PCR can be appropriately selected based on the sequence information of the present invention disclosed herein and can be synthesized using conventional methods. The amplified DNA / RNA fragments can be separated and purified using conventional methods such as gel electrophoresis.

[0109] The present invention also relates to vectors containing the polynucleotides of the present invention, host cells genetically engineered using the vectors of the present invention or the Candida antarcticis lipase B (CalB) protein coding sequence, and methods for generating the polypeptides of the present invention via recombinant technology.

[0110] Using conventional recombinant DNA technology, the polynucleotide sequence of this invention can be used to express or produce recombinant Candida antarcticis lipase B (CalB) polypeptide. Generally, the following steps are involved:

[0111] Transformation or transduction of suitable host cells using the polynucleotide (or variant) encoding the Candida antarcticis lipase B (CalB) polypeptide of the present invention, or using a recombinant expression vector containing the polynucleotide; host cells cultured in a suitable culture medium; isolation and purification of the protein from the culture medium or cells.

[0112] In this invention, the polynucleotide sequence of *Candida antarcticis* lipase B (CalB) can be inserted into a recombinant expression vector. The term "recombinant expression vector" refers to bacterial plasmids, bacteriophages, yeast plasmids, plant cell viruses, mammalian cell viruses such as adenoviruses, retroviruses, or other vectors well-known in the art. Any plasmid and vector can be used as long as it can replicate and remain stable within the host. An important characteristic of expression vectors is that they typically contain an origin of replication, a promoter, a marker gene, and translational control elements.

[0113] Methods well known to those skilled in the art can be used to construct expression vectors containing the DNA sequence encoding Candida antarcticus lipase B (CalB) and suitable transcription / translation control signals. These methods include in vitro recombinant DNA techniques, DNA synthesis techniques, and in vivo recombination techniques. The DNA sequence can be efficiently ligated to an appropriate promoter in the expression vector to direct mRNA synthesis. Representative examples of these promoters include: the lac or trp promoter of Escherichia coli; the PL promoter of λ phage; eukaryotic promoters including the CMV immediate early promoter, the HSV thymidine kinase promoter, early and late SV40 promoters, LTRs of retroviruses, and other known promoters that control gene expression in prokaryotic or eukaryotic cells or their viruses. The expression vector also includes a ribosome binding site for translation initiation and a transcription terminator.

[0114] In addition, the expression vector preferably contains one or more selective marker genes to provide phenotypic traits for selecting host cells for transformation, such as dihydrofolate reductase, neomycin resistance, and green fluorescent protein (GFP) for eukaryotic cell culture, or tetracycline or ampicillin resistance for Escherichia coli.

[0115] Vectors containing the appropriate DNA sequence and appropriate promoter or control sequence can be used to transform appropriate host cells so that they can express proteins.

[0116] The host cell can be a prokaryotic cell, such as a bacterial cell; a lower eukaryotic cell, such as a yeast cell; or a higher eukaryotic cell, such as a mammalian cell. Representative examples include: Escherichia coli, Streptomyces; Salmonella typhimurium bacterial cells; fungal cells such as yeast; plant cells; Drosophila S2 or Sf9 insect cells; and animal cells such as CHO, COS, 293 cells, or Bowes melanoma cells.

[0117] In another preferred embodiment, suitable host cells include Gram-positive bacteria such as Bacillus subtilis, Gram-negative bacteria such as Escherichia coli, actinomycetes such as Streptomyces, yeasts such as Saccharomyces cerevisiae, and fungi such as Aspergillus, whose cells are all commonly used host cells for recombinant vectors.

[0118] When the polynucleotides of this invention are expressed in higher eukaryotic cells, the insertion of an enhancer sequence into the vector will enhance transcription. Enhancers are cis-acting factors of DNA, typically approximately 10 to 300 base pairs, that act on the promoter to enhance gene transcription. Examples include the SV40 enhancer (100 to 270 base pairs) located late on the replication origin side, the polyoma enhancer located late on the replication origin side, and adenovirus enhancers.

[0119] Those skilled in the art are well aware of how to select appropriate vectors, promoters, enhancers, and host cells.

[0120] Transformation of host cells with recombinant DNA can be performed using conventional techniques well known to those skilled in the art. When the host is a prokaryote such as *E. coli*, competent cells capable of uptake DNA can be harvested after the exponential growth phase and treated with CaCl2, the steps of which are well known in the art. Another method is to use MgCl2. If desired, transformation can also be performed using electroporation. When the host is a eukaryote, the following DNA transfection methods can be used: calcium phosphate coprecipitation, conventional mechanical methods such as microinjection, electroporation, liposome packaging, etc.

[0121] The obtained transformants can be cultured using conventional methods to express the polypeptide encoded by the gene of this invention. Depending on the host cells used, the culture medium can be selected from various conventional media. Culture is carried out under conditions suitable for host cell growth. Once the host cells have grown to an appropriate cell density, the selected promoter is induced using a suitable method (such as temperature adjustment or chemical induction), and the cells are cultured for a further period.

[0122] The recombinant peptides used in the methods described above can be expressed intracellularly, on the cell membrane, or secreted extracellularly. If desired, the recombinant proteins can be separated and purified using various separation methods based on their physical, chemical, and other properties. These methods are well known to those skilled in the art. Examples of these methods include, but are not limited to: conventional refolding treatment, treatment with protein precipitants (salting out), centrifugation, permeation, ultrafiltration, ultracentrifugation, molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, high-performance liquid chromatography (HPLC), and various other liquid chromatography techniques, as well as combinations of these methods.

[0123] application

[0124] This invention also provides the application of the Candida antarcticis lipase B (CalB) and its mutants, particularly in the catalytic kinetic resolution reaction of methyl (R,S)-1,4-benzodioxane-2-carboxylate.

[0125] A preferred example is its use in the synthesis of pharmaceutical intermediates. Typically, the *Candida antarcticis* lipase B (CalB) of the present invention can be used to prepare (S)-1,4-benzodioxane or (R)-1,4-benzodioxane-like products.

[0126] (S)-1,4-benzodioxane compounds catalyzed by *Candida antarcticis* lipase B (CalB) are important intermediates in the synthesis of antihypertensive drugs such as doxazosin and protoprazor, while (R)-1,4-benzodioxane compounds are important intermediates in the synthesis of antidepressant drugs such as MCK-242. The *Candida antarcticis* lipase B (CalB) and its mutants of this invention can catalyze the production of enantiomeric compounds of (S)-1,4-benzodioxane or (R)-1,4-benzodioxane.

[0127] Because certain mutant Candida antarcticis lipase B (CalB) of the present invention has significantly improved enantioselectivity for (S)-1,4-benzodioxane compounds (e.g., D223N / A225K), it can be used for in vitro enzymatic synthesis of (S)-1,4-benzodioxane-2-carboxylic acid.

[0128] Because certain mutant Candida antarctic lipase B (CalB) of the present invention has reversed enantioselectivity for (R)-1,4-benzodioxane compounds (e.g., E188D / I189M), it can be used for the in vitro enzymatic synthesis of (R)-1,4-benzodioxane-2-carboxylic acid.

[0129] Typically, the present invention provides a method for synthesizing enantiomeric pure compounds of (S)-1,4-benzodioxane or (R)-1,4-benzodioxane using the *Candida antarcticis* lipase B (CalB) of the present invention in vitro. In the method of the present invention, the corresponding products (S)-1,4-benzodioxane or (R)-1,4-benzodioxane enantiomeric pure compounds can be directly generated from the starting material (R,S)-1,4-benzodioxane-2-carboxylate under the catalysis of *Candida antarcticis* lipase B (CalB).

[0130] Preferably, the *Candida antarcticis* lipase B (CalB) or the *Candida antarcticis* lipase B (CalB) mutant provided in the second aspect above. Under optimized conditions, the conversion rate of the *Candida antarcticis* lipase B (CalB)-catalyzed reaction is 47.5%, ee s The value reached 93.9%.

[0131] Preferably, the enzyme loading is 18 μg / mL.

[0132] Preferably, the substrate concentration is 1 mg / mL substrate.

[0133] Preferably, the biphase solvent system is n-butanol / phosphate buffer (20:80, v / v).

[0134] Preferably, the temperature is 37°C.

[0135] Preferably, the reaction time is 50 minutes.

[0136] Method for synthesizing (S)-1,4-benzodioxane-2-carboxylic acid

[0137] This invention also provides a method for the in vitro synthesis of (S)-1,4-benzodioxane-2-carboxylic acid using the *Candida antarcticis* lipase B (CalB) of this invention. Typically, this method includes: using methyl (R,S)-1,4-benzodioxane-2-carboxylate as a starting material, (S)-1,4-benzodioxane-2-carboxylic acid can be directly generated under the catalysis of *Candida antarcticis* lipase B (CalB).

[0138] Experiments show that the enzyme of the present invention is particularly suitable for the in vitro enzymatic synthesis of (S)-1,4-benzodioxane-2-carboxylic acid.

[0139] Preferably, the *Candida antarcticus* lipase B (CalB) or the reductive amination enzyme mutant provided in the second aspect above. Under the same conditions, the *Candida antarcticus* lipase B (CalB) mutant exhibits significantly improved enantioselectivity in the production of (S)-1,4-benzodioxane-2-carboxylic acid from (R,S)-1,4-benzodioxane-2-carboxylic acid, with a conversion rate of 47.5%. s The value reached 93.9%.

[0140] Preferably, the enzyme loading is 18 μg / mL.

[0141] Preferably, the substrate concentration is 1 mg / mL substrate.

[0142] Preferably, the biphase solvent system is n-butanol / phosphate buffer (20:80, v / v).

[0143] Preferably, the temperature is 37°C.

[0144] Preferably, the reaction time is 50 minutes.

[0145] The main advantages of this invention include:

[0146] (a) The corresponding (S)-1,4-benzodioxane-2-carboxylic acid was synthesized in vitro using the *CalB* mutant of *Candida antarcticus* as described in this invention via enzymatic synthesis, with a conversion rate of 47.5%. s The value can reach 93.9%.

[0147] (b) Using the Candida antarcticis lipase B (CalB) described in this invention, (S)-1,4-benzodioxane-2-carboxylic acid was synthesized in vitro via an enzymatic method. s The enantioselectivity can reach 69.3%; under the same conditions, its mutant significantly improves the enantioselectivity for the catalytic synthesis of (S)-1,4-benzodioxane-2-carboxylic acid, reaching 93.9%.

[0148] (c) The enantiomeric (S)-1,4-benzodioxane-2-carboxylic acid was successfully synthesized in vitro using the Candida antarcticis lipase B (CalB) described in this invention.

[0149] (d) The Antarctic Candida lipase B (CalB) and its mutant obtained by this invention can be used to synthesize enantiomeric (S)-1,4-benzodioxane-2-carboxylic acid by in vitro enzymatic method. This is a new production method that is different from the existing production technology. The production process is simplified, has low consumption, and is green and environmentally friendly.

[0150] The present invention will be further described in detail below with reference to specific embodiments and data. It should be understood that these embodiments are merely illustrative and not intended to limit the scope of the invention in any way. Experimental methods in the following embodiments, unless otherwise specified, are generally performed under conventional conditions, such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or as recommended by the manufacturer. Unless otherwise stated, percentages and fractions are weight percentages and weight fractions.

[0151] Materials and reagents

[0152] General description of the source of the biological materials described in this invention:

[0153] Primer synthesis: All primers used in this invention were synthesized and prepared by Shanghai Qingke Biotechnology Co., Ltd.

[0154] The PrimeSTAR Max DNA polymerase used in the experiment was purchased from TakaRa; the DNA gel extraction kit and plasmid miniprep kit were purchased from Axygen.

[0155] Example 1: Construction of Candida antarcticis lipase B (CalB)

[0156] Specifically, in this embodiment, the present invention is based on Candida antarcticis lipase B (CalB) and its coding sequence. Its amino acid sequence is shown in SEQ ID No:1:

[0157]

[0158] The CalB gene underwent codon optimization to facilitate expression in E. coli. The optimized coding sequence is shown in SEQ ID No:4:

[0159]

[0160] The sequence shown in SEQ ID No:4 was synthesized using a whole-genome synthesis method, with NcoⅠ and XhoⅠ restriction sites added to both ends. This full-length sequence was then cloned into the NcoⅠ and XhoⅠ restriction sites of the commercially available pET-22b(+) plasmid.

[0161] Example 2: Expression and purification of Candida antarcticis lipase B

[0162] The recombinant expression plasmids containing the selected genes were heat-shock transformed into *E. coli* Rosetta(DE3) competent cells for gene expression and protein purification. The recombinant bacteria were cultured to OD200. 600When the concentration is 0.6-0.8, add IPTG to a final concentration of 0.01 mM and induce culture overnight at a low temperature of 15°C and 220 rpm.

[0163] The bacterial cells were collected by centrifugation and resuspended in 20 mM Tris-HCl buffer (pH 8.0, 500 mM NaCl, 20 mM imidazole). 250 mL of cultured cells were finally resuspended in 40 mL of buffer and homogenized using a high-pressure homogenizer (4–6 °C, 700 Pa). The cell lysis buffer was then centrifuged at 12,000 rpm for 30 min (4 °C), and the supernatant was collected. This centrifugation was repeated at 12,000 rpm for 30 min (4 °C). The supernatant was then used to purify the protein using a Ni-NTA column affinity chromatography. Impurities were eluted with 20 mM Tris-HCl buffer (pH 8.0, 500 mM NaCl, 50 mM imidazole), and the target protein was eluted with 20 mM Tris-HCl buffer (pH 8.0, 500 mM NaCl, 200 mM imidazole). The eluted protein was then concentrated and desalted to obtain the purified protein.

[0164] The purified protein was stored in 50 mM PBS buffer (pH 7.5), and the purified protein was detected by SDS-PAGE electrophoresis. The protein concentration was determined using the Bradford Protein Assay Kit (Shanghai Sangon Biotech).

[0165] The results are as follows Figure 1 As shown in the figure. The results indicate that a clear band was obtained at 35 kDa, which is basically consistent with the predicted size of the recombinant protein (34.3 kDa), indicating that the target protein CalB has been purified.

[0166] Example 3: Construction and Enantioselectivity Determination of Candida Antarctica Lipase B Mutant. In this example, the enantioselectivity of Candida Antarctica lipase B in catalyzing the kinetic resolution of methyl (R,S)-1,4-benzodioxane-2-carboxylate was studied. Site selection was performed using literature mining and structural analysis. Key sites were combined using interaction distance network analysis to conduct directed evolutionary modification of the enzyme, resulting in a mutant capable of efficiently catalyzing the kinetic resolution of methyl (R,S)-1,4-benzodioxane-2-carboxylate.

[0167] Using recombinant plasmid pET22b-CalB as a template, and complementary oligonucleotides (a mixture of NDT, VHG, and TGG in a specific ratio) with a 22c-trick mutation site as primers, full-plasmid PCR amplification was performed using Primestar high-fidelity enzyme to obtain the recombinant plasmid with the specific mutation site. The primer sequences are as follows:

[0168] The mutants corresponding to the substitution of aspartic acid at position 223 and alanine at position 223 in SEQ NO:2 with 19 other amino acids respectively: the mutants corresponding to the substitution of glutamic acid at position 188 and isoleucine at position 189 with 19 other amino acids.

[0169] The amplification system consisted of 20 ng of recombinant plasmid template, 1 μl each of primers (10 μm), 25 μl of PrimeSTAR Max DNA polymerase, and double-distilled water to a final volume of 50 μl. The amplification conditions were: 98℃ pre-denaturation for 3 min, 98℃ denaturation for 15 s, 55℃ annealing for 15 s, and 72℃ extension for 2 min, for a total of 25 cycles, followed by a final extension at 72℃ for 10 min. After the reaction, the amplified products were detected by 1% agarose gel electrophoresis. The products were purified and recovered using a PCR product purification kit, and digested with DpnI enzyme (NEB) at 37℃ for 2 hours to degrade the initial template. The digested products were transformed into E. coli Rosetta (DE3) competent cells, plated on LB agar plates containing 100 μg / mL ampicillin and 34 μg / mL chloramphenicol, and incubated overnight at 37℃. Positive clones were screened and sequenced for verification. A saturated mutant recombinant strain of *Candida antarctica* with a specified site for lipase B was obtained.

[0170] The purified protein of the saturated mutant of Candida antarcticis lipase B at a specified site was obtained according to the method in Example 2.

[0171] The reaction system for determining the enantioselectivity of the mutant was as follows: 4 μg / mL of the mutant purified enzyme and 1 mg / mL of (R,S)-1,4-benzodioxane-2-carboxylate in a butanol / phosphate buffer (20:80, v / v) biphase system. The final reaction volume was brought to 500 μL using 50 mM PBS (pH 9.0) buffer. The reaction was incubated at 30 °C with shaking at 220 rpm for 30 min. Then, 1 mL of methyl tert-butyl ether was added for extraction, followed by shaking for 10 min, centrifugation at 12000 rpm for 10 min at 4 °C, and rotary evaporation of the supernatant organic phase. The mixture was reconstituted in 200 μL of hexane / isopropanol (90:10, v / v), filtered through a 0.22 μm organic filter, and analyzed by HPLC using hexane / isopropanol (90:10, v / v) as the mobile phase to determine substrate consumption.

[0172] The method for HPLC detection of recombinant protein kinetics to resolve methyl (R,S)-1,4-benzodioxane-2-carboxylate is as follows: using... An IG column was used with a sample loading volume of 10 μL. The mobile phase was n-hexane / isopropanol (90:10, v / v), the flow rate was 1 mL / min, the column temperature was 30 °C, and the UV detection wavelength was 220 nm. Mutants showing resolution were selected for subsequent Sanger sequencing identification.

[0173] The results are as follows Figure 2 As shown in the figure. The results yielded 24 mutants with higher enantiomeric selectivity than wild-type or reversed enantiomeric selectivity relative to wild-type, including D223N / A225K and D223G / A225W. DNA sequencing results showed that mutants with improved enantiomeric selectivity mainly originated from the D223 / A225 site, while those with reversed enantiomeric selectivity mainly originated from the E188 / I189 site. Of the 24 mutants, 17 showed the same enantiomeric preference as the wild-type, exhibiting a greater tendency to hydrolyze (S)-configured substrates to generate (S)-acids and possessing improved corresponding selectivity (ee). s The enantioselectivity (EE) value was 1.38-2.46 times higher than that of the wild type. Most of the mutants exhibiting increased enantioselectivity originated from the D223 / A225 site. The main mutations in D223 were Gly, Ser, Asn, Arg, and Thr residues, while the main mutations in A225 were Lys, Trp, Tyr, and Arg residues with larger branches. The mutant D223N / A225K exhibited the best enantioselectivity, with an EE value significantly higher than that of the wild type. s The value increased to 2.46 times. The E188Q / I189T at the E188 / I189 site also showed a 2.06-fold increase in ee compared to the wild type. s value.

[0174] Surprisingly, mutants at the E188 / I189 sites (except for E188Q / I189T) exhibit reversed enantiomeric selectivity. For example... Figure 3 As shown, compared to the wild type, seven mutants, including E188D / I189M, E188N / I189Y, and E188D / I189Y, exhibited enantioselective reversal (i.e., ee). s (Values ​​are negative), indicating a preference for hydrolyzing (R)-type substrates to generate (R)-acids. The order of preference after reversal is: E188D / I189M > E188N / I189Y > E188D / I189Y > E188D / I189F. This suggests that mutating the E at position 188 to asparagine Asn(N) or aspartic acid Asp(D), and / or mutating the I at position 189 to Met(M), Phe(F), or Tyr(Y) can help reverse the enantiomeric selectivity of the mutant protein, i.e., a preference for hydrolyzing (R)-type substrates.

[0175] Example 4: Optimization of kinetic resolution conditions for (R,S)-1,4-benzodioxane-2-carboxylate using the Antarctic Candida lipase B mutant.

[0176] In this embodiment, the reaction conditions for the catalytic kinetics resolution of the optimal mutant D223N / A225K obtained in Example 3 were optimized.

[0177] 4.1 Effect of temperature on enzyme-catalyzed reactions

[0178] The reaction system consisted of 500 μL of a mixture including 4 μg / mL of wild-type or mutant substrate, methyl (R,S)-1,4-benzodioxane-2-carboxylate at a final concentration of 1 mg / mL, 100 μL of n-butanol, and 50 mmol / L PBS buffer (pH 7.5) to a final volume of 500 μL. After reacting the samples at 20, 30, 37, and 42 °C for 30 min, 1 mL of methyl tert-butyl ether was added for extraction. The mixture was shaken for 10 min, then centrifuged at 12000 rpm for 10 min at 4 °C. The supernatant organic phase was collected and rotary evaporated. The solution was reconstituted with 200 μL of n-hexane / isopropanol (90:10, v / v), filtered through a 0.22 μm organic filter, and HPLC was performed using n-hexane / isopropanol (90:10, v / v) as the mobile phase to determine the conversion and ee of the substrate kinetics for wild-type and optimal mutant catalytic resolution. s The effects of temperature on the kinetic separation response of wild-type and optimal mutants were analyzed.

[0179] The results are as follows Figure 4 As shown, both the wild-type and the mutant D223N / A225K had the highest ees values ​​at 37℃, reaching 10.3% and 29.3%, respectively.

[0180] 4.2 Effect of phosphate / organic solvent biphase system on enzyme-catalyzed reactions

[0181] Under determined optimal temperature and other conditions, the effects of different organic solvent types on the catalytic reaction were investigated. The catalytic characteristics of the purified wild-type and optimal mutant were detected by HPLC. Using 20% ​​(v / v) DMSO, n-butanol, isopropanol, ethyl acetate, and chloroform as co-solvents, the reaction was carried out at 37℃ with an enzyme concentration of 4 μg / mL for 30 min, and the reaction conversion and ee were then measured. s Values ​​were used to determine the optimal co-solvent type; subsequently, the conversion and ee of the wild-type and optimal mutant were tested at optimal organic solvent percentages of 0%, 5%, 20%, 50%, 80%, and 100% (v / v). s The value is used to determine the effect of the percentage of the optimal solvent in the reaction system on the reaction.

[0182] The results are as follows Figure 5 and Figure 6 As shown, the optimal solvent system for wild-type and mutant D223N / A225K is a two-phase solvent system of n-butanol / phosphate buffer (20:80, v / v).

[0183] 4.3 Kinetic resolution time progression of methyl (R,S)-1,4-benzodioxane-2-carboxylate catalyzed by the optimal mutant

[0184] After determining the optimal single-factor conditions such as temperature, type of organic solvent, and ratio of organic solvent, the effects of enzyme amount and time on the catalytic reaction were explored through preliminary experiments. Finally, the conversion rate and ee of the catalytic reaction of (R,S)-1,4-benzodioxane-2-carboxylate were detected at 10, 20, 30, 40, 50, and 60 min using an enzyme amount of 18 μg / mL. s The values ​​were used to obtain the kinetic separation time curves of wild type and mutant, and the optimal reaction conditions of mutant were obtained.

[0185] The results are as follows Figure 7 As shown, at 50 minutes, the wild-type ee s The value was 69.3%, at which point the conversion rate was 48.4%, while the mutant D223N / A225K achieved approximately 93.9% ee. s At this value, the conversion rate is approximately 47.5%.

[0186] All documents mentioned in this invention are incorporated herein by reference as if each document were individually incorporated by reference. Furthermore, it should be understood that after reading the foregoing teachings of this invention, those skilled in the art can make various alterations or modifications to this invention, and these equivalent forms also fall within the scope defined by the appended claims.

[0187] Sequence information

[0188] SEQ ID No:1 (Wild-type CalB amino acid sequence)

[0189]

[0190] SEQ ID No:2 (D223N / A225K mutant CalB amino acid sequence)

[0191]

[0192] SEQ ID No:3 (E188Q / I189T mutant CalB amino acid sequence)

[0193]

[0194] SEQ ID No:4 (Wild-type CalB DNA sequence)

[0195] sequence list <110> Shanghai Jiao Tong University <120> Evolution of Antarctic Candida lipase B and its catalytic synthesis of (S)-1,4-benzodioxane <130> P2022-0635 <160> 4 <170> SIPOSequenceListing 1.0 <210> 1 <211> 317 <212> PRT <213> Candida antarctica <400> 1 Leu Pro Ser Gly Ser Asp Pro Ala Phe Ser Gln Pro Lys Ser Val Leu 1 5 10 15 Asp Ala Gly Leu Thr Cys Gln Gly Ala Ser Pro Ser Ser Val Ser Lys 20 25 30 Pro Ile Leu Leu Val Pro Gly Thr Gly Thr Thr Gly Pro Gln Ser Phe 35 40 45 Asp Ser Asn Trp Ile Pro Leu Ser Thr Gln Leu Gly Tyr Thr Pro Cys 50 55 60 Trp Ile Ser Pro Pro Pro Phe Met Leu Asn Asp Thr Gln Val Asn Thr 65 70 75 80 Glu Tyr Met Val Asn Ala Ile Thr Ala Leu Tyr Ala Gly Ser Gly Asn 85 90 95 Asn Lys Leu Pro Val Leu Thr Trp Ser Gln Gly Gly Leu Val Ala Gln 100 105 110 Trp Gly Leu Thr Phe Phe Pro Ser Ile Arg Ser Lys Val Asp Arg Leu 115 120 125 Met Ala Phe Ala Pro Asp Tyr Lys Gly Thr Val Leu Ala Gly Pro Leu 130 135 140 Asp Ala Leu Ala Val Ser Ala Pro Ser Val Trp Gln Gln Thr Thr Gly 145 150 155 160 Ser Ala Leu Thr Thr Ala Leu Arg Asn Ala Gly Gly Leu Thr Gln Ile 165 170 175 Val Pro Thr Thr Asn Leu Tyr Ser Ala Thr Asp Glu Ile Val Gln Pro 180 185 190 Gln Val Ser Asn Ser Pro Leu Asp Ser Ser Tyr Leu Phe Asn Gly Lys 195 200 205 Asn Val Gln Ala Gln Ala Val Cys Gly Pro Leu Phe Val Ile Asp His 210 215 220 Ala Gly Ser Leu Thr Ser Gln Phe Ser Tyr Val Val Gly Arg Ser Ala 225 230 235 240 Leu Arg Ser Thr Thr Gly Gln Ala Arg Ser Ala Asp Tyr Gly Ile Thr 245 250 255 Asp Cys Asn Pro Leu Pro Ala Asn Asp Leu Thr Pro Glu Gln Lys Val 260 265 270 Ala Ala Ala Ala Leu Leu Ala Pro Ala Ala Ala Ala Ile Val Ala Gly 275 280 285 Pro Lys Gln Asn Cys Glu Pro Asp Leu Met Pro Tyr Ala Arg Pro Phe 290 295 300 Ala Val Gly Lys Arg Thr Cys Ser Gly Ile Val Thr Pro 305 310 315 <210> 2 <211> 317 <212> PRT <213]] Artificial Sequence <400> 2 Leu Pro Ser Gly Ser Asp Pro Ala Phe Ser Gln Pro Lys Ser Val Leu 1 5 10 15 Asp Ala Gly Leu Thr Cys Gln Gly Ala Ser Pro Ser Ser Val Ser Lys 20 25 30 Pro Ile Leu Leu Val Pro Gly Thr Gly Thr Thr Gly Pro Gln Ser Phe 35 40 45 Asp Ser Asn Trp Ile Pro Leu Ser Thr Gln Leu Gly Tyr Thr Pro Cys 50 55 60 Trp Ile Ser Pro Pro Pro Phe Met Leu Asn Asp Thr Gln Val Asn Thr 65 70 75 80 Glu Tyr Met Val Asn Ala Ile Thr Ala Leu Tyr Ala Gly Ser Gly Asn 85 90 95 Asn Lys Leu Pro Val Leu Thr Trp Ser Gln Gly Gly Leu Val Ala Gln 100 105 110 Trp Gly Leu Thr Phe Phe Pro Ser Ile Arg Ser Lys Val Asp Arg Leu 115 120 125 Met Ala Phe Ala Pro Asp Tyr Lys Gly Thr Val Leu Ala Gly Pro Leu 130 135 140 Asp Ala Leu Ala Val Ser Ala Pro Ser Val Trp Gln Gln Thr Thr Gly 145 150 155 160 Ser Ala Leu Thr Thr Ala Leu Arg Asn Ala Gly Gly Leu Thr Gln Ile 165 170 175 Val Pro Thr Thr Asn Leu Tyr Ser Ala Thr Asp Glu Ile Val Gln Pro 180 185 190 Gln Val Ser Asn Ser Pro Leu Asp Ser Ser Tyr Leu Phe Asn Gly Lys 195 200 205 Asn Val Gln Ala Gln Ala Val Cys Gly Pro Leu Phe Val Ile Asn His 210 215 220 Lys Gly Ser Leu Thr Ser Gln Phe Ser Tyr Val Val Gly Arg Ser Ala 225 230 235 240 Leu Arg Ser Thr Thr Gly Gln Ala Arg Ser Ala Asp Tyr Gly Ile Thr 245 250 255 Asp Cys Asn Pro Leu Pro Ala Asn Asp Leu Thr Pro Glu Gln Lys Val 260 265 270 Ala Ala Ala Ala Leu Leu Ala Pro Ala Ala Ala Ala Ile Val Ala Gly 275 280 285 Pro Lys Gln Asn Cys Glu Pro Asp Leu Met Pro Tyr Ala Arg Pro Phe 290 295 300 Ala Val Gly Lys Arg Thr Cys Ser Gly Ile Val Thr Pro 305 310 315 <210> 3 <211> 317 <212> PRT <213> Artificial Sequence <400> 3 Leu Pro Ser Gly Ser Asp Pro Ala Phe Ser Gln Pro Lys Ser Val Leu 1 5 10 15 Asp Ala Gly Leu Thr Cys Gln Gly Ala Ser Pro Ser Ser Val Ser Lys 20 25 30 Pro Ile Leu Leu Val Pro Gly Thr Gly Thr Thr Gly Pro Gln Ser Phe 35 40 45 Asp Ser Asn Trp Ile Pro Leu Ser Thr Gln Leu Gly Tyr Thr Pro Cys 50 55 60 Trp Ile Ser Pro Pro Pro Phe Met Leu Asn Asp Thr Gln Val Asn Thr 65 70 75 80 Glu Tyr Met Val Asn Ala Ile Thr Ala Leu Tyr Ala Gly Ser Gly Asn 85 90 95 Asn Lys Leu Pro Val Leu Thr Trp Ser Gln Gly Gly Leu Val Ala Gln 100 105 110 Trp Gly Leu Thr Phe Phe Pro Ser Ile Arg Ser Lys Val Asp Arg Leu 115 120 125 Met Ala Phe Ala Pro Asp Tyr Lys Gly Thr Val Leu Ala Gly Pro Leu 130 135 140 Asp Ala Leu Ala Val Ser Ala Pro Ser Val Trp Gln Gln Thr Thr Gly 145 150 155 160 Ser Ala Leu Thr Thr Ala Leu Arg Asn Ala Gly Gly Leu Thr Gln Ile 165 170 175 Val Pro Thr Thr Asn Leu Tyr Ser Ala Thr Asp Gln Thr Val Gln Pro 180 185 190 Gln Val Ser Asn Ser Pro Leu Asp Ser Ser Tyr Leu Phe Asn Gly Lys 195 200 205 Asn Val Gln Ala Gln Ala Val Cys Gly Pro Leu Phe Val Ile Asp His 210 215 220 Ala Gly Ser Leu Thr Ser Gln Phe Ser Tyr Val Val Gly Arg Ser Ala 225 230 235 240 Leu Arg Ser Thr Thr Gly Gln Ala Arg Ser Ala Asp Tyr Gly Ile Thr 245 250 255 Asp Cys Asn Pro Leu Pro Ala Asn Asp Leu Thr Pro Glu Gln Lys Val 260 265 270 Ala Ala Ala Ala Leu Leu Ala Pro Ala Ala Ala Ala Ile Val Ala Gly 275 280 285 Pro Lys Gln Asn Cys Glu Pro Asp Leu Met Pro Tyr Ala Arg Pro Phe 290 295 300 Ala Val Gly Lys Arg Thr Cys Ser Gly Ile Val Thr Pro 305 310 315 <210> 4 <211> 954 <212> DNA <213> Candida antarctica <400> 4 ctaccttccg gttcggaccc tgccttttcg cagcccaagt cggtgctcga tgcgggtctg 60 acctgccagg gtgcttcgcc atcctcggtc tccaaaccca tccttctcgt ccccggaacc 120 ggcaccacag gtccacagtc gttcgactcg aactggattc ccctctcaac gcagttgggt 180 tacacaccct gctggatctc acccccgccg ttcatgctca acgacaccca ggtcaacacg 240 gagtacatgg tcaacgccat caccgcgctc tacgctggtt cgggcaacaa caaacttccc 300 gtgcttacct ggtcccaggg tggtctggtt gcacagtggg gtctgacctt cttccccagt 360 atcaggtcca aggtcgatcg acttatggcc tttgcgcccg actacaaggg caccgtcctc 420 gccggccctc tcgatgcact cgcggttagt gcaccctccg tatggcagca aaccaccggt 480 tcggcactca ccaccgcact ccgaaacgca ggtggtctga cccagatcgt gcccaccacc 540 aacctctact cggcgaccga cgagatcgtt cagcctcagg tgtccaactc gccactcgac 600 tcatcctacc tcttcaacgg aaagaacgtc caggcacagg ccgtgtgtgg gccgctgttc 660 gtcatcgacc atgcaggctc gctcacctcg cagttctcct acgtcgtcgg tcgatccgcc 720 ctgcgctcca ccacgggcca ggctcgtagt gcagactatg gcattacgga ctgcaaccct 780 cttcccgcca atgatctgac tcccgagcaa aaggtcgccg cggctgcgct cctggcgccg 840 gcagctgcag ccatcgtggc gggtccaaag cagaactgcg agcccgacct catgccctac 900 gcccgcccct ttgcagtagg caaaaggacc tgctccggca tcgtcacccc ctga 954

Claims

1. A method for enzymatic catalytic kinetic resolution, characterized in that, Including the following steps: (a) In the presence of the Candida antarcticis lipase B mutant, the substrate... (R,S) methyl 1,4-benzodioxane-2-carboxylate undergoes an enzymatic resolution reaction to form a product containing the trans-form. (S) The reaction mixture of -1,4-benzodioxane-2-carboxylic acid, Wherein, in the reaction mixture, (S) The quantity A1 of -1,4-benzodioxane-2-carboxylic acid (compound of formula (S)-2) and (R) The ratio of the amount of -1,4-benzodioxane-2-carboxylic acid A2 to A1 / A2 is ≥2:1; Furthermore, the mutant is a D223N / A225K mutant Candida antarcticis lipase B, and its amino acid sequence is shown in SEQ ID No:

2.

2. The method as described in claim 1, characterized in that, In step (a), the reaction is carried out in a liquid-phase reaction system; the solvent of the liquid-phase reaction system consists of the following components: DMSO, n-butanol, isopropanol, ethyl acetate, and chloroform.

3. The method as described in claim 1, characterized in that, In step (a), the reaction temperature is 30-45°C.

4. The method as described in claim 1, characterized in that, In step (a), the reaction time is 40-60 min.

5. An isolated or purified Candida antarcticis lipase B mutant, characterized in that, The mutant is D223N / A225K mutant Candida antarcticis lipase B, and its amino acid sequence is shown in SEQ ID No:

2.

6. An isolated polynucleotide, characterized in that, The polynucleotide encodes the Antarctic Candida lipase B mutant as described in claim 5.

7. A carrier, characterized in that, The carrier contains the polynucleotide as described in claim 6.

8. A genetically engineered host cell, characterized in that, The host cell contains the vector of claim 7, or the polynucleotide of claim 6 is integrated into its genome.

9. The use of the *Candida antarcticis* lipase B mutant according to claim 5, characterized in that, The mutant was used for catalytic kinetic resolution reactions or for preparing catalysts for catalytic kinetic resolution reactions.

Citation Information

Patent Citations

  • Lipase variants and polynucleotides encoding same

    CN103827298A